Sagimet Biosciences
SGMT
86 hedge funds and large institutions have $85.2M invested in Sagimet Biosciences in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 10 closing their positions.
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
45% more call options, than puts
Call options by funds: $1.9M | Put options by funds: $1.31M
19% more funds holding
Funds holding: 72 → 86 (+14)
5.68% more ownership
Funds ownership: 40.76% → 46.43% (+5.7%)
2% less capital invested
Capital invested by funds: $86.7M → $85.2M (-$1.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$5.74M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$5.61M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.19M |
| 4 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$1.59M |
| 5 |
BlackRock
New York
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$3.6M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.59M |
| 3 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$2.23M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.55M |
| 5 |
Millennium Management
New York
|
-$1.36M |
SGMT Hedge Fund Activity: Q4 2025 in Review
86 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q4 2025, worth a combined $85.2M — down 1.7% from $86.7M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SGMT positions and 10 closed out — a net gain of 16 holders — while 27 added to existing stakes and 16 trimmed.
The largest buyer was Affinity Asset Advisors, adding an estimated $5.74M. The largest seller was Woodline Partners, cutting an estimated $3.6M.
- 86 institutional investors held Sagimet Biosciences (SGMT) as of Q4 2025, up from 72 in Q3 2025.
- Funds reported $85.2M of Sagimet Biosciences stock for Q4 2025, down 1.7% quarter-over-quarter.
- 26 funds opened new Sagimet Biosciences positions in Q4 2025 and 10 closed out, a net change of +16 holders.
- The largest Sagimet Biosciences buyer in Q4 2025 was Affinity Asset Advisors, an estimated $5.74M added.
- The largest Sagimet Biosciences seller in Q4 2025 was Woodline Partners, an estimated $3.6M sold.
Based on aggregated 13F filings for Q4 2025.